SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.57 - $1.31
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$53.05M
Enterprise Value-$981.97K
Total Cash (Recent Filing)$59.26M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding79,442,635
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$3.50Price Target Upside430.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Asset Monetization PotentialMid-stage-ready antifungal candidate SCY-247 could be partnered or divested to generate non-dilutive funding and accelerate other development programs.
Clinical Differentiation And SafetySCY-770 targets autosomal dominant polycystic kidney disease with a different mechanism that could compete with existing therapy while potentially avoiding liver-safety issues.
Pipeline DiversificationAcquisition of SCY-770 shifts company focus into a high-value rare disease area and broadens the development pipeline beyond antifungals.
Bears Say
Analyst Valuation PressureDevelopment and revenue risks have prompted analyst adjustments that could lead to downgrades and increased downward pressure on the stock.
Clinical And Regulatory RiskSCY-770 remains early in clinical development, creating exposure to trial failures and regulatory setbacks that could negatively affect valuation.
Revenue Forecast UncertaintyAnalysts applied meaningful revenue risk adjustments due to uncertainty in translating early clinical results into future commercial sales.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.56 and its highest was $1.31 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $53.05M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 17, 2026 which is in 88 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 11, 2026. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.297.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.06.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 79,442,635 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went down -5.34%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (430.30% Upside)
$3.50 (430.30% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-57.16%
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$3.50
▲(430.30% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
3.48% Insiders
6.40% Mutual Funds
31.16% Other Institutional Investors
56.84% Public Companies and
Individual Investors